Myeloablative allo-SCT decreases relapse incidence (RI) in ALL. Reduced intensity conditioning (RIC) may extend allo-SCT to older and less fit patients. Sixty-nine ALL patients reported to the BSBMT underwent fludarabine-based RIC allo-SCT, 38 from unrelated donors (UD). Forty-four patients received alemtuzumab. ALL was in CR in 64 patients (93%). This was a second or third SCT in 23 patients. Two-year OS and PFS were 36% and 32%, respectively. In multivariate analysis male recipients demonstrated better OS and PFS (hazard ratio (HR) ¼ 0.42, P ¼ 0.008 and HR ¼ 0.45, P ¼ 0.012, respectively). Two-year TRM was 29%: higher with younger age (HR ¼ 0.97/year, P ¼ 0.041), female recipient (HR ¼ 2.55, P ¼ 0.049) and increasing grade of acute GVHD (HR ¼ 1.87, P ¼ 0.001). Two-year RI was 38% and was lower in patients with acute and chronic GVHD (HR ¼ 0.62 per increasing grade, P ¼ 0.035 and HR ¼ 0.52, P ¼ 0.025, respectively). Long-term ALL-free survival is achievable following fludarabine-based RIC allo-SCT. The association between GVHD and decreased RI suggests the presence of a GVL effect.
INTRODUCTION
Developments in induction chemotherapy for adult ALL have resulted in CR rates in excess of 90%. [1] [2] [3] Fewer than 50% of patients, however, are alive 5 years from diagnosis, with the majority of deaths being due to relapsed disease. 3, 4 Survival following ALL relapse is dismal, 5 thus a key improvement in outcome may result from optimization of postremission consolidation therapy. Myeloablative conditioned (MAC) allo-SCT improves survival in patients in CR1 in both Ph-positive and negative disease, 6 due to a reduction in the relapse incidence (RI). However, while RI is also reduced in older, higher risk patients, there is not a significant benefit in OS due to higher rates of TRM in the high-risk patients, negating the benefit of the allo-SCT associated reduction in RI. 6 There is evidence for a GVL effect in ALL; GVHD is associated with lower RI and allo-SCT provides significant benefit over autologous transplant. 3, 7, 8 A reduced intensity conditioning (RIC) approach may reduce RI and lower TRM, extending applicability to older patients and those with comorbidities. Several retrospective studies have examined RIC allo-SCT for ALL. Early series were small and included high numbers of patients with advanced or refractory disease, OS in these cohorts ranged between 18 and 40% at 1-3 years. [9] [10] [11] Both the European Group for Blood and Marrow Transplantation (EBMT) and the Centre for International Blood and Marrow Transplant Research (CIBMTR) have published larger series comparing RIC and MAC allo-SCT in ALL. 12, 13 The CIBMTR study of both sibling and unrelated donors (UD) reported no significant difference in TRM and RI for RIC and MAC (3 year OS 38% vs 43%, respectively). 13 The EBMT survey of sibling transplants in patients 445 years old only, reported a significantly increased RI and significantly decreased TRM in the RIC group, leading to comparable OS (48% RIC, 45% MAC).
12
A prospective study of T replete fludarabine/melphalan conditioned RIC allo-SCT in CR1/2 ALL found a 3 year PFS of 62.6%.
14 There are few published results of in vivo T-cell depleted allografts for ALL. A BSBMT survey of alemtuzumab use in MAC allo-SCT for adults with ALL in CR1 reported PFS of 59% at 5 years. 15 T-cell depletion in RIC allo-SCT, however, may be much more significant as GVL is central to disease control in the RIC setting. A CIBMTR study of anti-thymocyte globulin (ATG) and alemtuzumab use in RIC conditioning, which included a small number of ALL transplants, concluded that although GVHD was diminished by T-cell depletion, there was a price to be paid in terms of increased RI and decreased PFS. 16 To assess the current UK experience of RIC allo-SCT in ALL, we undertook a retrospective analysis of the outcomes of RIC allo-HSCT reported to the BSBMT.
PATIENTS AND METHODS Eligibility
eligible. Initially, 116 transplants in 112 patients from 29 centres were identified. On contacting the centres, 16 patients from 3 centres were excluded as they had received MAC conditioning, a further 3 centres did not participate in the study. Five centres did not return data. The remaining 18 centres provided data on 77 transplants in 75 patients. The first RIC transplant only was considered for analysis, excluding two transplants. A further six patients were excluded: three stem cell 'top-ups' (defined as a stem cell infusion given as therapy for poor engraftment or engraftment failure following an allo-SCT procedure and given without further cytotoxic conditioning therapy), two diagnosis not ALL, and one due to lack of data-leaving 69 patients.
Definitions and statistical analysis
Neutrophil and plt engraftment were defined as the first of 3 consecutive days with a neutrophil count of X0.5 Â 10 9 /L and plt count X50 Â 10 9 /L without transfusion support, respectively. OS and PFS were defined, as time from transplant to death or to disease relapse or death, respectively and were calculated using the Kaplan À Meier method with survivors censored at last followup. RI and TRM were defined as time from transplant to relapse or death in continuous remission, respectively and were analysed using the cumulative incidence function treating each as a competing risk for the other. Univariate analysis used the log-rank test or Cox regression for continuous variables. Multivariate analysis used Cox regression for OS/PFS and the method of Fine and Grey for RI/TRM. Variables included in the models were recipient and donor gender, recipient age at transplant, Karnofsky status at transplant, recipient and donor CMV serostatus, white cell count at diagnosis, Ph/BCR-ABL status, prior use of tyrosine kinase inhibitor therapy, disease status at transplant (CR1 vs beyond CR1), number of induction chemotherapy courses to first CR, first vs second transplant, transplant centre size, use of in vivo T-cell depletion, acute GVHD grade and extent of chronic GVHD (treating GVHD as a time dependent covariate). Statistical analysis was performed using Stata, 18 and R software. 19 
RESULTS

Patient characteristics and engraftment
Patient characteristics are shown in Table 1 . The median age at transplant was 42 years and the median duration of followup of survivors was 17 months (range 3-129 months). Thirty-one patients were originally included in the UKALL XII/ECOG E2993 study and a further three were stated as following the study protocol outside the trial. Of 66 patients with cytogenetic/ molecular data available, 23 (35%) were Ph/BCR-ABL positive. Ninety-three per cent of patients were in CR at transplant. UD were used for 55% of patients. Fludarabine was used in all conditioning regimens, most frequently (in 65%) combined with melphalan. Alemtuzumab was used in 64% transplants at a median total dose of 60 mg (range 30-120 mg). Sixty-six (96%) patients engrafted and median times to neutrophil and plt recovery were 15 days (range 5-25) and 18 days (range 9-55), respectively. Three (4%) patients experienced primary engraftment failure, one of these patients received in vivo T-cell depletion with antithymocyte globulin, the other two were T-cell replete transplants.
This was a first RIC transplant for all patients but some had received a prior SCT, either autologous (n ¼ 8) or allogeneic (n ¼ 15); making this the second SCT in 22 patients (32%) and the third in 1 patient (1.4%). Considering the 15 prior allo-SCTs, all were MAC SCTs with TBI-based conditioning in 14/15. Stem cell source was BM (n ¼ 6), PBSC (n ¼ 8) or both BM and PBSC (n ¼ 1). The donor was a matched sibling (n ¼ 11) or UD (n ¼ 4). In the case of the sibling recipients, the same donor was used in the subsequent RIC allo-SCT in 10 cases and an UD was used in 1 case. For the four patients receiving an UD first allo-SCT, the subsequent RIC used an UD in all cases, we do not have data on whether this was the same or a different UD. Disease status at transplant was CR in 14/15 (CR1 À 10, CR2 À 4) and progressive disease in 1/15. The median time between first SCT and RIC was 27 months (range 2-122 months).
Of the eight prior auto-SCT, all received myeloablative conditioning which was TBI-based in 5/8. Disease status at transplant was CR in 7/8 (CR1 À 6, CR2 À 1) and primary induction failure in 1/8. The median time between the auto-SCT and RIC allo-SCT was 21 months (range 6-137 months). For the single patient receiving two prior SCT both were autologous; the first was performed in CR2 and the second in CR3, 96 months following the first transplant and 40 months before the RIC allo-SCT.
Sixty-three patients received central nervous system (CNS) prophylaxis before allo-SCT, three received no prophylaxis and data were unavailable for three patients. The UKALL XII/ECOG E2993 protocol 3 specified regular intrathecal MTX, three doses of i.v. MTX at 3 g/m 2 and craniospinal irradiation. CNS prophylaxis received comprised full UKALL XII/ECOG E2993 regimen in 10 patients, craniospinal irradiation (with or without high-dose MTX and intrathecal chemotherapy) in six patients, high-dose MTX or cytarabine and intrathecal chemotherapy in 12 patients and intrathecal chemotherapy only in 28 patients. Seven patients received unspecified CNS prophylaxis.
Indication for RIC Patient age and prior SCT were the most frequently stated indications for RIC. Thirty-three (48%) patients were o40 years of age at transplant, of these 21 received this RIC allo-SCT as a second SCT, of whom 3 had comorbidities at the time of transplant. Of the 12 patients o40 years for whom this was the first SCT, the indication for RIC conditioning was a comorbid condition in seven, Down syndrome in two, extent of previous treatment in one and physician choice (not further specified) in two patients. For 33 of 36 patients X40 years old at transplant this was their first allo-SCT. Of these the indication for RIC conditioning was stated as age in 26 patients, comorbidity in six patients and plt refractoriness in 1 patient. In the 26 cases where age was the primary indication, seven patients also had a comorbidity recorded as a secondary indication for RIC. Survival PFS is shown in Figure 1 . Two-year estimates of OS and PFS were 36% (95% CI: 23-49) and 32% (95% CI: 20-45), respectively. Median OS and PFS were 15 and 12 months, respectively. In univariate analysis: recipient gender (2-year OS male 48%, female 23%, P ¼ 0.008); recipient/donor CMV status (2-year OS negative/ negative 38%, negative/positive 0%, positive/negative 31% and positive/positive 47%, P ¼ 0.016) and chronic GVHD (2-year OS no chronic GVHD 27%, limited chronic GVHD 64%, extensive chronic GVHD 63%, P ¼ 0.04) were significantly associated with OS. In multivariate analysis, only male recipient gender remained significantly associated with improved OS (Table 2) . PFS was significantly associated with recipient gender in univariate (2-year PFS male 45%, female 18%, P ¼ 0.012) and multivariate analysis ( Table 2 ). Patient age, UD transplant, alemtuzumab use or dose of alemtuzumab were not associated with altered survival outcomes. OS and PFS were not significantly different for Ph-positive and negative disease: OS 32 vs 35% (P ¼ 0.68) and PFS 34 vs 32% (P ¼ 0.74), respectively. PFS following second or third SCT was not significantly worse than when the RIC allo-SCT was the first transplant performed (P ¼ 0.266, Figure 2 ), although this could relate to relatively small patient numbers. Two-year OS and PFS for CR1 vs XCR2 were 40% vs 29% (P ¼ 0.27) and 30% vs 28% (P ¼ 0.2), respectively.
Relapse Two-year cumulative RI was 38% (95% CI: 26-51). Twenty-four patients relapsed, with BM the commonest site. Six patients experienced extramedullary relapse in the CNS (n ¼ 4), skin (n ¼ 1) and both CNS and skin in the sixth patient. Relapse was isolated to the extramedullary site in four cases and was associated with medullary relapse in two cases. For the five CNS relapses, RIC allografting for ALL: an analysis from the BSBMT PG Medd et al pretransplant CNS prophylaxis had comprised craniospinal irradiation and intrathecal chemotherapy in one patient, high-dose MTX with intrathecal chemotherapy in one patient and intrathecal chemotherapy only in three patients. None of these patients had CNS À ALL involvement at diagnosis. RI was significantly lower in patients with acute GVHD in univariate analysis (2-year RI 47% (95% CI: 32-61) and 9% (95% CI: 0-32) P ¼ 0.006 for grades 0/I and II À IV acute GVHD, respectively. This was also the case for chronic GVHD: 2-year RI 51% (95% CI: 30-69) for patients without chronic GVHD, 29% (95% CI: 12-49) for patients with chronic GVHD, P ¼ 0.012). These associations persisted in multivariate analysis ( Table 2 ). The effect of GVHD on RI is shown in Figure 3 . RI was not significantly associated with T-cell depletion (2-year RI 35% (95% CI: 14-56%) vs 40% (95% CI: 23-57%) for T-cell replete vs T-cell depleted allo-SCT, nor was there an effect of alemtuzumab dose on RI (P ¼ 0.84). There was no significant association between donor type (related/unrelated) and RI (P ¼ 0.65).
Transplant-related mortality Two-year TRM was 29% (95% CI: 18-41). In univariate analysis the following associated significantly with TRM: patient gender (2-year TRM 42% (95% CI: 24-59) and 17% (95% CI: 6-32%) for female and male recipients, respectively, P ¼ 0.049) and acute GVHD (2-year TRM 21% (95% CI: 11-33) and 57% (95% CI: 27-78) for grades 0/I and II À IV acute GVHD, respectively, P ¼ 0.039). In addition, TRM was also slightly higher in younger patients and for second transplants, although neither association reached statistical significance (HR per year of age 0.978, P ¼ 0.093 and HR 1.82, P ¼ 0.087, respectively). In multivariate analysis acute GVHD, female recipient and younger age at transplant were associated with increased TRM (Table 2) . Causes of death in remission were (n): infection (8: adenovirus 2, bacterial pneumonia 1, staphylococcal bacteraemia 1, not specified 4), GVHD (7), multiple organ failure (2), graft failure (1) and veno-occlusive disease (1). A regression model was used to estimate whether the higher TRM in younger patients was independent of number of transplant. Considering age and number of transplant the association with age approaches statistical significance (P ¼ 0.069) while number of transplant was not significantly associated with TRM (P ¼ 0.802). GVHD Acute GVHD developed in 32% of patients, the cumulative incidence of significant (grades II-IV) acute GVHD was 22%. Incidence of severe acute GVHD (grades III-IV) was 5%. Strikingly 13 patients died before day 100; of the remainder, chronic GVHD incidence was 43%, and extensive chronic GVHD incidence was 24%. Of 35 alemtuzumab-based allo-SCT surviving 4day 100, 14 (43%) developed chronic GVHD, which was limited in eight patients (23%) and extensive in six (17%). DLI Nine patients (15%) received DLI after allo-SCT. Indications were (n, %) mixed chimerism (3, 33%), decline/loss of chimerism (2, 22%), planned per protocol (1, 11%), frank relapse (1, 11%) and unknown (2, 22%). At the time of reporting, four patients (44%) had achieved full donor chimerism, four (44%) remained with mixed chimerism and one patient (11%) had lost their graft following DLI. There were no reported episodes of GVHD following the first dose of DLI. N =23 P =0.025 Figure 3 . Effect of (a) acute and (b) chronic GVHD on cumulative RI.
DISCUSSION
In this study, containing a high proportion of second transplants, we demonstrate that medium to long-term disease control can be achieved in about a third of patients following RIC allo-SCT for ALL, comparable to several earlier series. 10, 11, 20, 21 Surprisingly, TRM incidence was higher in younger patients and likely independent of number of transplant. This presumably represents greater comorbidity in this group who would otherwise be candidates for a MAC allo-SCT. The rate of TRM reported here for the group overall is disappointingly high for RIC allografts, but is consistent with that reported for other series. 13 The antileukaemia therapeutic effect of RIC allo-SCT may be dependent upon the immunological GVL effect mediated after the transplant. Studies have repeatedly demonstrated GVL effects following MAC allo-SCT for ALL. 6, 7, 22, 23 There is some evidence that RI is higher following RIC. 12 However, responses to DLI have been demonstrated following RIC allo-SCT, 10 and GVHD has been reported to be associated with lower RI [12] [13] [14] and improved OS. 21, 24 In this study, we demonstrate a reduced RI associated with both acute and chronic GVHD after RIC allo-SCT for ALL. Generally chronic GVHD is thought to be more strongly associated with GVL than acute GVHD although interestingly Marks et al. 13 noted a stronger association between acute GVHD and decreased ALL RI than between chronic GVHD and RI. It may be that in the case of ALL early GVHD and associated GVL is more important in establishing disease control than in other haematological malignancies. Although in our study, GVHD was associated with decreased RI, there was no association with improved PFS. The likely explanation for this observation is that GVHD was also associated with increased TRM, negating the benefit of GVL in reducing RI. Of note, chronic GVHD was associated with improved OS, at least in univariate analysis. Strategies to separate the GVL effect from the toxicities of GVHD remain an elusive but universally desired goal of allogeneic SCT. Approaches possible using current technology which might be considered in future studies include: (1) minimal residual disease monitoring to guide whether to offer allo-SCT, whether to use in vivo T-cell depletion, how to modulate post-transplant immunosuppression and when to use DLI; (2) the use of planned DLI to augment donor lymphoid immunity following T-cell depleted allo-SCT and (3) the incorporation of immunomodulatory drugs into the posttransplant schedule.
Given the importance of GVL the use of alemtuzumab is of particular interest. The CIBMTR study suggested that in vivo T-cell depletion was associated with impaired outcome mediated by an increase in TRM rather than RI. 13 Two series evaluating fludarabine-melphalan T replete RIC for ALL reported OS rates of 61 and 64%, with chronic GVHD incidences of 86 and 66%. 14, 24 Alemtuzumab decreases GVHD, but is associated with increased RI and decreased PFS, and this effect persists even after adjusting for the presence of chronic GVHD. 16 Although dose reduction of alemtuzumab is feasible 26, 27 it remains to be seen whether such a strategy will allow GVHD control with diminished RI. Despite the above, in this study we did not find an impact of alemtuzumab use or dose on PFS or RI. This may be due to the use of close monitoring of donor chimerism allowing early use of DLI. The effect of mixed chimerism on relapse has not been prospectively studied but is being assessed in the UKALL14 trial (http://public. ukcrn.org.uk/search/StudyDetail.aspx?StudyID=7471). Finally, it must be remembered that alemtuzumab has antileukaemic activity in ALL 28 and studies demonstrating its association with increased RI based mainly on patients with other diagnoses may not be safely extrapolated to ALL.
The survival benefit found for males in this study is consistent with previous reports in adult ALL where male gender has been associated with reduced RI after allo-SCT. 29 Data from the UKALL XII/ECOG E2993 study found male gender associated with improved CR rates and improved survival in patients relapsing after initial induction therapy. 3 Two issues of particular concern for clinicians contemplating RIC allo-SCT for ALL are its efficacy in Ph-positive disease and its efficacy in preventing CNS relapse in the absence of TBI-based conditioning. As with previous studies of RIC for ALL, 25 we have demonstrated equivalence in outcome for Ph-positive and negative disease. The majority (75%) of Ph-positive patients in this series had received therapy with a tyrosine kinase inhibitor before allo-SCT and this therapy may be critical in enabling patients with Ph-positive disease to reach transplant 25, 30, 31 CNS relapse occurred in 5 of 63 patients (7%) in this study, despite pretransplant CNS directed therapy. This supports the use of post-RIC transplant CNS directed therapy, for example with planned post-SCT intrathecal chemotherapy.
In conclusion, in this group of patients, including a significant number who had received heavy pretreatment, a fludarabinebased RIC allo-SCT was associated with a 2-year OS of 36%. Outcomes were equivalent for UD and sibling donors and for Ph-positive and negative disease. The association between acute and chronic GVHD and reduced RI suggests the presence of a GVL effect after RIC allo-SCT. These data support the further investigation of fludarabine-/melphalan-/alemtuzumabconditioned RIC allo-SCT in the UKALL14 clinical trial. Only prospective evaluation of this treatment strategy in large numbers of patients will demonstrate its role in the management of adults with ALL.
